SG Americas Securities LLC lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 38.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,960 shares of the biopharmaceutical company’s stock after buying an additional 3,873 shares during the quarter. SG Americas Securities LLC’s holdings in Celldex Therapeutics were worth $475,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Celldex Therapeutics by 35.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,610 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,459 shares in the last quarter. NTB Financial Corp bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at $266,000. Teacher Retirement System of Texas lifted its stake in shares of Celldex Therapeutics by 16.6% during the 4th quarter. Teacher Retirement System of Texas now owns 7,151 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 1,019 shares in the last quarter. HC Advisors LLC boosted its holdings in Celldex Therapeutics by 49.1% in the 4th quarter. HC Advisors LLC now owns 8,183 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 2,694 shares during the period. Finally, Handelsbanken Fonder AB bought a new stake in Celldex Therapeutics during the fourth quarter valued at about $344,000. 98.61% of the stock is owned by hedge funds and other institutional investors.
Celldex Therapeutics Trading Up 6.7 %
NASDAQ CLDX opened at $36.69 on Friday. The stock’s 50 day moving average is $26.70 and its 200 day moving average is $29.86. Celldex Therapeutics, Inc. has a 12 month low of $19.85 and a 12 month high of $57.20. The stock has a market cap of $1.72 billion, a PE ratio of -21.46 and a beta of 2.43.
Analyst Ratings Changes
Separately, HC Wainwright upped their price objective on Celldex Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, July 1st.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
- Get a free copy of the StockNews.com research report on Celldex Therapeutics (CLDX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.